← boardnext 2029-06-01
BYSI
BeyondSpring Pharmaceuticals Inc.distress 6/10 · elevated risk$1.11-2%today-53% from 52w high
Lead: Non-Small Cell Lung Cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$8M
Runway
0.4 yrs
Shares 1y
+2%
Price & events
-33.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-13.3%
1W
-31.1%
1M
-33.1%
3M
-31.5%
6M
-40.6%
1Y
-47.6%
2Y
-88.6%
5Y
-90.9%
All
Overview
- Market Cap
- $45.64M
- Volume
- 1.14K
- 52 Week Range
- $1.11 – $2.35
- Total Shares
- 41.12M
- Float Shares
- 31.95M
- Short %
- 6.51%
- % Held by Insiders
- 14.26%
- % Held by Institutions
- 14.55%
- RVOL
- 0.04x
- Beta
- 0.42
Pipeline stages · 1 programs
Plinabulin, Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-06-01 Estimated 50% readout ~2029-08-15 | Phase 3 | Plinabulin, Docetaxel | Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | — | not yet recruiting |
Catalyst news & presentations · 5
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- ASCO 2026conferencedata presentationsecondaryPlinabulin · Presentation of Phase 2 study update demonstrating durable clinical benefit.PR wire
- 2025-09-22partnershipSEED Therapeutics completed second close of Series A-3 Preferred Shares sale, raising $6M from third-party investors.SEC 8-K
- 2025-01-24partnershipBeyondSpring sells ~8.33M preferred shares of SEED Therapeutics for ~$35.4M in three installments.SEC 8-K
- 2025-01-24partnershipBeyondSpring Inc. entered into a Preferred Share Purchase Agreement to sell ~8.33M Series A-1 Preferred Shares of SEED Therapeutics Inc. for ~$35.4M.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Non-Small Cell Lung Cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- RVMDRevolution Medicines, Inc.$40.3B · D1
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- MAIAMAIA Biotechnology, Inc.$78M · D5
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-06Form 4 BeyondSpring Inc For: 6 July By Investing.com - Investing.com Canada
- 2026-07-06BeyondSpring (BYSI) director receives 100,000 stock options grant - Stock Titan
- 2026-07-06BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares - Stock Titan
- 2026-07-06BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing - Stock Titan
- 2026-07-06BeyondSpring (BYSI) CEO awarded 100,000 stock options at $1.75 strike price - Stock Titan
- 2026-07-05BYSI Q1 2026 Earnings: Narrowing Net Loss Reinforces Strategic Focus - Consensus Miss Rate - dars.gov.et
- 2026-06-29BeyondSpring (BYSI) Q1 2026 Earnings: Net Loss of -$0.05 Per Share as Clinical Programs Advance - Revenue Guidance Range - DonanımHaber
- 2026-06-29BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.